GlassScriptPhysician profile
Stacey Rene Sanchez
NPI 1801314281
$19,278.91
in general payments reported to CMS, 2019-2025
42 companies · $4,216 in 2025
The $4,216 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,807 · 2022: $5,108 · 2023: $4,189 · 2024: $2,960 · 2025: $4,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $140 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,095.68 |
| Travel and Lodging | $140.41 |
| Education | $127.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $5,128.81 | 2022-2024 | Senza |
| Medtronic, INC. | $3,009.36 | 2022-2025 | Synchromedii, Vectris Surescan, Intellis Adaptivestim |
| Novo Nordisk INC | $1,909.88 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,523.80 | 2021-2023 | |
| Globus Medical, INC. | $1,011.68 | 2025 | Senza |
| Lilly USA, LLC | $858.63 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $595.71 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Dexcom, INC. | $586.07 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $511.36 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $441.82 | 2021-2025 | |
| Biotronik Nro, INC. | $361.90 | 2025 | Prospera |
| Janssen Pharmaceuticals, INC | $309.88 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $304.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.50 | 2021-2023 | |
| Horizon Therapeutics Plc | $249.59 | 2021-2023 | Krystexxa |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.